SNAIL-MEDIATED SIGNALING IN HUMAN PROSTATE CANCER

人类前列腺癌中蜗牛介导的信号传导

基本信息

  • 批准号:
    7959171
  • 负责人:
  • 金额:
    $ 28.48万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-07-01 至 2010-06-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Epithelial-mesenchymal transition (EMT) occurs during normal embryonic development and epithelial tumor progression. Several factors associated with EMT contribute to motility, invasion, and angiogenesis, and may be important therapeutic targets for prostate cancer metastasis. Understanding the factors that contribute to EMT and prostate cancer metastasis is crucial for development of cancer therapies. For example, Snail transcription factor has been identified as an important factor that can induce EMT in breast and colon cancer. However, the role of EMT in prostate cancer is not well defined and good EMT models are lacking. Recently we have established an EMT model for prostate cancer progression using the ARCaP cell model overexpressing Snail. The goal of this proposal is to study the role of Snail transcription factor in prostate cancer progression and metastasis. We have found that Snail-induced EMT in prostate cancer cells involves reactive oxygen species (ROS) and receptor activator of NFkB (RANKL), two factors that are important in cancer disease progression and bone metastatic lesions, respectively. This proposal will elucidate the biological significance of Snail, with emphasis of its role in prostate cancer bone metastasis. In addition, we will characterize the signaling pathway of Snail-induced EMT, and finally examine the effect of antagonizing Snail expression on tumor aggressiveness in vitro and in vivo. We believe these studies will identify Snail as an attractive therapeutic target not only for EMT during primary tumor progression but also for bone metastatic lesions at the secondary site.
这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者(PI)可能从另一个NIH来源获得了主要资金, 因此可以在其他CRISP条目中表示。所列机构为 中心,但不一定是研究者所在的机构。 上皮-间质转化(EMT)发生在正常胚胎发育和上皮肿瘤进展过程中。与EMT相关的几个因素有助于运动、侵袭和血管生成,并且可能是前列腺癌转移的重要治疗靶点。了解导致EMT和前列腺癌转移的因素对于癌症治疗的发展至关重要。例如,Snail转录因子已被鉴定为可在乳腺癌和结肠癌中诱导EMT的重要因子。 然而,EMT在前列腺癌中的作用还没有很好的定义,缺乏良好的EMT模型。最近,我们使用过表达Snail的ARCaP细胞模型建立了前列腺癌进展的EMT模型。本研究的目的是研究Snail转录因子在前列腺癌进展和转移中的作用。我们已经发现,蜗牛诱导的EMT在前列腺癌细胞涉及活性氧(ROS)和NF κ B受体激活剂(RANKL),这两个因素是重要的癌症疾病进展和骨转移病变,分别。本研究将阐明Snail的生物学意义,特别是其在前列腺癌骨转移中的作用。此外,我们将表征Snail诱导的EMT的信号通路,并最终在体外和体内研究拮抗Snail表达对肿瘤侵袭性的影响。我们相信这些研究将确定Snail不仅是原发性肿瘤进展期间EMT的有吸引力的治疗靶点,而且也是次要部位骨转移性病变的有吸引力的治疗靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Valerie Odero-Marah其他文献

Valerie Odero-Marah的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Valerie Odero-Marah', 18)}}的其他基金

HMGA2 mediates resistance to therapy in prostate cancer
HMGA2 介导前列腺癌治疗耐药
  • 批准号:
    10622747
  • 财政年份:
    2023
  • 资助金额:
    $ 28.48万
  • 项目类别:
RCMI@Morgan: Center for Urban Health Disparities Research and Innovation
RCMI@摩根:城市健康差异研究与创新中心
  • 批准号:
    10372112
  • 财政年份:
    2019
  • 资助金额:
    $ 28.48万
  • 项目类别:
RCMI@Morgan: Center for Urban Health Disparities Research and Innovation
RCMI@摩根:城市健康差异研究与创新中心
  • 批准号:
    10671920
  • 财政年份:
    2019
  • 资助金额:
    $ 28.48万
  • 项目类别:
RCMI@Morgan: Center for Urban Health Disparities Research and Innovation
RCMI@摩根:城市健康差异研究与创新中心
  • 批准号:
    10452009
  • 财政年份:
    2019
  • 资助金额:
    $ 28.48万
  • 项目类别:
RCMI@Morgan: Center for Urban Health Disparities Research and Innovation
RCMI@摩根:城市健康差异研究与创新中心
  • 批准号:
    10113369
  • 财政年份:
    2019
  • 资助金额:
    $ 28.48万
  • 项目类别:
RCMI@Morgan: Center for Urban Health Disparities Research and Innovation
RCMI@摩根:城市健康差异研究与创新中心
  • 批准号:
    10599734
  • 财政年份:
    2019
  • 资助金额:
    $ 28.48万
  • 项目类别:
The Role of Snail Signaling in Prostate Cancer Metastasis
蜗牛信号在前列腺癌转移中的作用
  • 批准号:
    8495467
  • 财政年份:
    2013
  • 资助金额:
    $ 28.48万
  • 项目类别:
Snail Signalling in Human Prostate Cancer
人类前列腺癌中的蜗牛信号传导
  • 批准号:
    8544046
  • 财政年份:
    2012
  • 资助金额:
    $ 28.48万
  • 项目类别:
SNAIL-MEDIATED SIGNALING IN HUMAN PROSTATE CANCER
人类前列腺癌中蜗牛介导的信号传导
  • 批准号:
    8357123
  • 财政年份:
    2011
  • 资助金额:
    $ 28.48万
  • 项目类别:
SNAIL-MEDIATED SIGNALING IN HUMAN PROSTATE CANCER
人类前列腺癌中蜗牛介导的信号传导
  • 批准号:
    8166161
  • 财政年份:
    2010
  • 资助金额:
    $ 28.48万
  • 项目类别:

相似海外基金

Intelligent Breast Cancer DiagnOsis and MonItoring Therapeutic Response Training Network (CanDoIt)
智能乳腺癌诊断和监测治疗反应训练网络(CanDoIt)
  • 批准号:
    EP/Y03693X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.48万
  • 项目类别:
    Research Grant
From single-cell transcriptomic to single-cell fluxomic: characterising metabolic dysregulations for breast cancer subtype classification
从单细胞转录组到单细胞通量组:表征乳腺癌亚型分类的代谢失调
  • 批准号:
    EP/Y001613/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.48万
  • 项目类别:
    Research Grant
Preclinical validation of synthetic biomolecules to treat Breast Cancer from AI-enabled discovery of novel lncRNA therapeutic targets.
通过人工智能发现新型 lncRNA 治疗靶点,对合成生物分子治疗乳腺癌进行临床前验证。
  • 批准号:
    10110204
  • 财政年份:
    2024
  • 资助金额:
    $ 28.48万
  • 项目类别:
    Launchpad
Quad negative breast cancerに対する新たなプレシジョン・メディシン治療戦略
四阴性乳腺癌精准医学治疗新策略
  • 批准号:
    24K11748
  • 财政年份:
    2024
  • 资助金额:
    $ 28.48万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
ESR1 mutation profiling identifies potential drivers of metastatic breast cancer
ESR1 突变分析确定了转移性乳腺癌的潜在驱动因素
  • 批准号:
    MR/X018199/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.48万
  • 项目类别:
    Research Grant
Spatial-BrTME: Multicellular spatial dynamics of immunotherapy response in breast cancer
Spatial-BrTME:乳腺癌免疫治疗反应的多细胞空间动力学
  • 批准号:
    EP/Y014995/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.48万
  • 项目类别:
    Research Grant
Development of comprehensive PET imaging for precise diagnosis of breast cancer
开发用于乳腺癌精确诊断的综合PET成像
  • 批准号:
    23H02856
  • 财政年份:
    2023
  • 资助金额:
    $ 28.48万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of internal radiation therapy agents for refractory breast cancer based on phase-shift using focused ultrasound
基于聚焦超声相移的难治性乳腺癌体内放射治疗剂的开发
  • 批准号:
    23H02866
  • 财政年份:
    2023
  • 资助金额:
    $ 28.48万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
The early detection of breast cancer using field cacerization.
使用现场癌症化早期检测乳腺癌。
  • 批准号:
    23K08094
  • 财政年份:
    2023
  • 资助金额:
    $ 28.48万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of CD44 bearing TJA-II binding glycans in therapy-resistant subset of triple negative breast cancer
携带 CD44 的 TJA-II 结合聚糖在三阴性乳腺癌耐药亚型中的作用
  • 批准号:
    23K06748
  • 财政年份:
    2023
  • 资助金额:
    $ 28.48万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了